Scinopharm TaiwanTPE:1789 -1.19%75 EV-to-FCF is 47.05 as of Jul. 08, 2026, which is 44% above its 10-year median of 32.68. GuruFocus rates TPE:1789 with a GF Score™ of 75/100 and a GF Value™ of NT$27.21 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 563 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 72.11% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Scinopharm Taiwan's Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$300 Mil. Therefore, Scinopharm Taiwan's EV-to-FCF for today is 47.05.
The historical rank and industry rank for Scinopharm Taiwan's EV-to-FCF or its related term are showing as below:
TPE:1789'
s EV-to-FCF Range Over the Past 10 Years
Min: -1432.44 Med: 32.68 Max: 175
Current: 47.18
During the past 13 years, the highest EV-to-FCF of Scinopharm Taiwan was 175.00. The lowest was -1432.44. And the median was 32.68.
TPE:1789's EV-to-FCF is ranked worse than 72.11% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs TPE:1789: 47.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scinopharm Taiwan's PE Ratio (TTM) for today is calculated as:
Scinopharm Taiwan's share price for today is NT$20.80.
Scinopharm Taiwan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Scinopharm Taiwan EV-to-FCF Related Terms
Scinopharm Taiwan EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's EV-to-FCF falls into.
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$300 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a EV-to-FCF of 47.05 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scinopharm Taiwan and its competitors. This is 44% above median its historical median of 32.68. According to the industry distribution chart, Scinopharm Taiwan ranks #406 out of 563 companies in the Drug Manufacturers industry, placing it in the top 72.1%.
Is Scinopharm Taiwan's EV-to-FCF too high?
Scinopharm Taiwan's current EV-to-FCF of 47.05 is 44% above median its 10-year median of 32.68. The Drug Manufacturers industry median EV-to-FCF is 20.85. Scinopharm Taiwan's value of 47.05 is 125.7% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #406 out of 563 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #406 out of 563 companies for EV-to-FCF. This places Scinopharm Taiwan in the lower half of its industry. The industry median EV-to-FCF is 20.85. Scinopharm Taiwan's value of 47.05 is 125.7% above this benchmark. While the company's 10-year median is 32.68 vs. the industry median of 20.85, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current EV-to-FCF of 47.05 is 125.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current EV-to-FCF is 47.05, which is 44% above median its own 10-year median of 32.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.21, compared to a current price of NT$20.80 — trading 23.6% below its estimated fair value. The current EV-to-FCF is 47.05, which is 44% above median its 10-year median of 32.68 and 125.7% above the Drug Manufacturers industry median of 20.85. Scinopharm Taiwan's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current EV-to-FCF is 47.05 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.80 is trading 23.6% below its estimated GF Value™ of NT$27.21.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
EV-to-FCF: 47.05 (44% above median its 10-year median of 32.68)
GF Value™: NT$27.21 vs. price of NT$20.80 (23.6% below fair value)
Industry Position: 125.7% above the Drug Manufacturers median (#406 of 563)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score
Get the complete analysis for TPE:1789
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
